Aug 15 vaccine timeline unrealistic, says Indian Academy of Sciences
The Indian Council of Medical Researchâ€™s (ICMRâ€™s) target of August 15 to â€œlaunch for public health useâ€ the Covid-19 vaccine candidate Covaxin is â€œunfeasibleâ€ and has raised â€œunrealisticâ€ hopes, some of Indiaâ€™s most eminent scientists said on Sunday.
The Council and the Fellowship of the Indian Academy of Sciences (IASc), a forum comprising 1,100 of the countryâ€™s foremost scientists, welcomed the development of the vaccine candidate by ICMR and Bharat Biotech, but cautioned against rushing into â€œany hasty solution that may compromise rigorous scientific processes and standardsâ€.
In a statement, the scientists said: â€œIASc welcomes the exciting development of a candidate vaccine and wishes that the vaccine is quickly made available for public use. However, as a body of scientists â€” including many who are engaged in vaccine development â€” IASc strongly believes that the announced timeline is unfeasible. This timeline has raised unrealistic hope and expectations in the minds of our citizens.â€
In a communication issued to clinical trial sites on July 2, ICMR Director-General Dr Balram Bhargava had said, â€œIt is envisaged to launch the vaccine for public health use latest by 15th August 2020 after completion of all clinical trials.â€ Following strong criticism from scientists and experts, ICMR said on Saturday that its letter â€œwas meant to cut unnecessary red tapeâ€, but remained silent on the August 15 timeline.
â€œWhile there is an unquestioned urgent need, vaccine development for use in humans requires scientifically executed clinical trials in a phased manner,â€ the IASc said. â€œThese trials involve evaluation of safety (Phase 1 trial), efficacy and side effects at different dose levels (Phase 2 trial) and confirmation of safety and efficacy in thousands of healthy people (Phase 3 trial) before its release for public use.â€
The development of a vaccine is a long, uncertain process that can run for decades and still yield no results. Even after three decades of research, a vaccine for HIV is still in phase III of clinical trials. The vaccine for mumps was one of the fastest to be developed, but it still received approval four years after trials began in 1963.
â€œWhile the administrative approvals can be put on a fast track, the scientific process in developing a vaccine needs to take its natural course,â€ Prof Partha P Majumder, president of the IASc Council, said. â€œFirst of all timelines for vaccines differ from vaccine to vaccine and cannot be predicted. Essentially, you cannot have a timeline for the launch of a vaccine because, for instance, if your first phase fails, then you have to discard the entire process and start afresh,â€ he said.
â€œAn injectable vaccine, which Covaxin will be, takes longer than an oral vaccine,â€ Prof Majumder said. â€œAnd the ICMR has announced a clinical trial period of a month â€“ this is unprecedented. This is unheard of and gives a bad name to the industry of biomedical research and pharmaceuticals. It is foolish and a shame on any organisation.â€™â€™
The Council had met on Saturday and decided to issue the statement â€œin the public interestâ€, Prof Majumder said.
In its statement, the IASc said that it â€œbelieves that the announced timeline is unreasonable and without precedentâ€ and that it â€œstrongly believes that any hasty solution that may compromise rigorous scientific processes and standards will likely have long-term adverse impacts of unforeseen magnitude on citizens of Indiaâ€.

ğŸ“£ The Indian Express is now on Telegram. Click here to join our channel (@indianexpress) and stay updated with the latest headlines
